Prevalence and Hematological Characteristics of Hemoglobinopathies

NCT07180836 | Completed DMC

• 1 other identifier: Ref no. 499/BKMC
• Study Type: observational
• Target: 839
• Locations: 1 country
• Sites: 1

Brief Summary

This study aimed to determine the prevalence and hematological characteristics of hemoglobinopathies in Mardan and surrounding districts of Khyber Pakhtunkhwa (KPK), Pakistan. A descriptive cross-sectional design was conducted at Mardan Medical Complex from January 2021 to January 2023. Blood samples were analyzed using High Performance Liquid Chromatography (HPLC) on the Bio-Rad D-10 analyzer, with complete blood counts performed using Sysmex XN1000. A total of 839 participants were enrolled in this study. The study highlights differences in hematological parameters across hemoglobinopathy types and provides region-specific data to inform public health interventions and screening programs.

Conditions

Hemoglobinopathies

Keywords

Hemoglobinopathies; Thalassemia; Sickle cell disease

Outcome Measures

Primary Outcomes (1)

• Prevalence of Hemoglobinopathies.

  Number of patients diagnosed with each hemoglobinopathy type (e.g., β-thalassemia trait, sickle cell disease, HbE).

  At the time of diagnosis / Single assessment at enrollment

Secondary Outcomes (1)

• Demographic Distribution of Hemoglobinopathies by Age, Gender, and Geographic Area

  At the time of diagnosis / Single assessment at enrollment

Study Arms (1)

Patients with Hemoglobinopathies in Mardan and Surrounding Districts

This cohort includes patients diagnosed with various hemoglobinopathies in Mardan and neighboring districts of Khyber Pakhtunkhwa, Pakistan. Participants were assessed for prevalence and hematological characteristics, including complete blood count parameters and disease-specific findings. No intervention was applied; this is an observational, cross-sectional study focused on identifying distribution patterns and hematological profiles of hemoglobinopathies in the study population

Other: No Intervention (Observational Study)

Interventions

No Intervention (Observational Study) OTHER

This is an observational, cross-sectional study. Patients with suspected or confirmed hemoglobinopathies were evaluated for prevalence and hematological characteristics using laboratory investigations, without any experimental treatment or therapeutic intervention applied.

Patients with Hemoglobinopathies in Mardan and Surrounding Districts

Eligibility Criteria

• Age: 1 Year - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

The study population consisted of patients referred for hemoglobinopathy testing to the Hematology Department, Mardan Medical Complex, Mardan, Khyber Pakhtunkhwa, Pakistan, over a period of two years (January 2021 to January 2023). A total of 839 participants were included in the analysis. These patients were of varying ages (mean age: 10.25 ± 4.87 years), with 55.89% male and 43.87% female, and represented different districts including Mardan, Charsadda, Dir, Buner, and Swabi, with the majority from Mardan (86.41%).

You may qualify if:

• All patients referred to the Hematology Department of Mardan Medical Complex for hemoglobinopathy testing between Jan 2021 - Jan 2023.
• Patients of either sex.
• Patients who underwent high-performance liquid chromatography (HPLC) and complete blood count (CBC) analysis.

You may not qualify if:

• Patients with incomplete or missing laboratory data (CBC or HPLC).
• Patients in whom hemoglobinopathy diagnosis could not be confirmed.
• Cases of anemia due to non-hemoglobinopathy causes (e.g., nutritional anemia, chronic disease).

Sponsors & Collaborators

• Bacha Khan Medical College: lead

Study Sites (1)

Mardan Medical Comlex, Mardan

Mardan, KPK, 23200, Pakistan

Location

MeSH Terms

Conditions

Hemoglobinopathies; Thalassemia; Anemia, Sickle Cell

Interventions

Observation

Condition Hierarchy (Ancestors)

Hematologic Diseases; Hemic and Lymphatic Diseases; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Anemia

Intervention Hierarchy (Ancestors)

Methods; Investigative Techniques

Study Officials

• Malik Shayan Ali Khan, MBBS

  Bacha Khan Medical College, Mardan.

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor (Principal Investigator)

Study Record Dates

• First Submitted: August 30, 2025
• First Posted: September 18, 2025
• Study Start: January 15, 2021
• Primary Completion: January 15, 2023
• Study Completion: January 20, 2023
• Last Updated: September 18, 2025

Record last verified: 2025-08

Locations

PA (1)